Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2382770 in diabetic kidney disease
NCT01113801Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2010
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of LY2382770 in diabetic kidney disease (DKD), sponsored by Eli Lilly and Company. Started Jul 2010; status: terminated.
02
Drugs
LY2382770
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT01113801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01113801.